Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.

The study reveals the below implications and techniques:

• Researchers used a new MRI technique to precisely measure brain electrical activity.
• By comparing brain scans before and after drinking, scientists identified specific areas affected by alcohol and how much brain activity slowed down.
• Participants were chosen to be regular social drinkers without alcohol addiction, ensuring the study focused on the effects of alcohol alone.
• MRI technology provided reliable data on brain activity changes caused by alcohol consumption.

How does the brain react to alcohol?

Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.

A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.

What is the connection between alcohol consumption and brain activity?

While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.

Alcohol and Brain activity: What does the study Imply?

The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.

Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.

UK health officials have identified seven more cases of meningitis, as part of the latest outbreak in Kent, taking the total number of cases to 27. They expect the numbers to rise in the coming days.

The UK Health Security Agency noted that it has expanded the Meningitis B vaccine regimen to everyone who has been offered preventative antibiotic treatment as part of this outbreak.

“15 laboratory cases are confirmed and 12 notifications remain under investigation, bringing the total to 27,” the UKHSA said in a statement.

“Currently, cases have been confirmed in students at 4 schools in Kent, as well as one student at a higher education institution in London (who is confirmed to be directly linked to the outbreak),” it added.

Two students -- a 21-year-old student at the University of Kent and a teenage student at a school in the town of Faversham have died in the outbreak.

A 9-month-old baby from Folkestone is reportedly battling for life in the intensive care unit.

Meanwhile, another university in the city confirmed a case of meningitis. The student at Canterbury Christ Church is believed to be a man who was at the nightclub and part of the initial cluster of 20 known cases, who visited Club Chemistry in Canterbury between March 5 and 7.

"We are not in the position yet to say definitively that it's been contained," Dr Anjan Ghosh, Director of Public Health at Kent County Council, told BBC Radio, adding that secondary transmissions needed to be ruled out.

Calling the outbreak “unprecedented”, Health Minister Wes Streeting said: “The number of suspected cases was expected to increase ‌in ⁠the coming days because the disease had a seven- to 10-day incubation period”, Reuters reported.

In a typical year, Britain sees about 350 cases, roughly one per day, according to government estimates.

In addition to the approximately 5,000 students who were initially contacted, vaccination will now be extended to everyone who has been offered preventative antibiotic treatment as part of this outbreak, the UKHSA said.

Why The Cases Are Rising

While it remains unclear why the outbreak has been so large, “the large number of cases all originating from what seems to be a single event” is particularly striking, Prof Robin May, the chief scientific officer at the UKHSA, told the BBC Breakfast.

May said that "there might be something about the kind of behaviors that individual people are doing." Another probable reason "is that the bacteria may have evolved to be better at transmitting".

Both the UKHSA and the European Centre for Disease Prevention and Control maintain that the risk of invasive meningococcal disease to the general population in Europe is "very low".

Also read: From Vaping to Worm Attack: 5 Unimaginable Ways to Contract Meningitis

Can The Outbreak Be Prevented?

The UKHSA noted that the key intervention to protect people and halt the spread remains for people to come forward for antibiotic treatment -- effective in preventing contraction and spreading in 90 percent of cases.

In addition, a targeted MenB vaccination program is also being introduced for longer-term protection.

“By extending the vaccination program to everyone who has been offered preventative antibiotics, we are taking an important additional step to protect those most likely to have been exposed. The message is simple: if you have had the antibiotic, you are also eligible for the vaccination,” said Professor Susan Hopkins, Chief Executive of the UKHSA.

However, Trish Mannes, UKHSA Regional Deputy Director for the South East, noted that even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.

The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhoea
• joint and muscle pain
• seizures.

The widespread use of Azithromycin to treat hospitalized patients during the COVID-19 pandemic increased the risk of antimicrobial resistance -- a major global health problem, according to a new study, published in the journal Nature Microbiology.

Scientists at the University of California-San Francisco (UCSF) noted that using azithromycin inappropriately for even a single day can trigger antibiotic resistance in the respiratory tract.

While azithromycin is effective against bacterial infections that cause strep throat, pneumonia, and sexually transmitted diseases, it does not work against viruses.

"We've known for years that antibiotics don't treat viral infections, but these results were striking," said Chaz Langelier, from UCSF.

"That we could see resistance genes turning on in the respiratory tract within a day tells us the consequences of unnecessary antibiotic use aren't theoretical or long-term. They're immediate, measurable, and biologically real," Langelier added.

The study analyzed nasal swabs of 1,164 adults hospitalized for COVID-19 to examine the changes that occurred in the microbiome of hospitalized patients who were treated for COVID.

Compared to people who received no antibiotics, patients administered azithromycin reported changes that persisted for more than a week. These include:

• Changes in the mix of microbes in the upper airway
• Decrease in harmless bacteria,
• Surge in potentially harmful bacteria such as Staphylococcus and Klebsiella.

Rising Global Antimicrobial Resistance

Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them.

It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections.

As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.

In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to the CDC's 2019 Antibiotic Resistance (AR) Threats Report.

The WHO, in a 2025 report, noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments.

Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent.

US Early Death Toll During COVID Much Higher

About 16 per cent of COVID-19 deaths went uncounted early in the pandemic in the US, according to a separate study, published by the journal Science Advances.

While about 840,000 COVID deaths were reported on death certificates in 2020 and 2021, the researchers using artificial intelligence (AI) decoded that as many as 155,000 unrecognised additional deaths likely occurred in that time outside of hospitals.

The US Food and Drug Administration has approved Johnson & Johnson's once-daily pill for psoriasis -- a chronic skin disease.

Icotyde is an interleukin-23 (IL-23) receptor antagonist approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older.

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily pill has been found safe and also delivers complete skin clearance.

Also Read: Why Regulatory Clarity Is Important for Safe Aesthetic Procedures in India

In the statement, J&J said that the approval will lead to a first-line systemic treatment of plaque psoriasis with a targeted oral peptide.

“Icotyde delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once‑daily pill, making it an easy addition to a patient’s routine,” said Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health.

The novel pill also aligns with the recent International Psoriasis Council guidance that suggests transitioning to systemic therapy if two cycles of topical medications applied for four weeks fail to bring meaningful improvement.

Icotyde will prove to be “a potential game‑changer for many adult and adolescent patients”, Gold said.

The FDA’s approval is based on an unprecedented body of evidence from the phase three clinical trial, which simultaneously evaluated Icotyde in adults and adolescents, and found it a safe and effective oral pill, and also better than injectables and topical creams.

According to analysts from Wall Street, Icotyde has "blockbuster potential," and the once-daily medication could capture significant market share from injectables like Skyrizi and J&J's own Tremfya, Reuters reported.

J&J is also studying the ⁠drug, chemically known as icotrokinra, for ulcerative colitis, psoriatic arthritis, and Crohn's disease.

What Is Psoriasis?

Psoriasis develops when the body makes skin cells too quickly. It causes skin cells to pile up and form visible patches or spots on the skin, which may be itchy or painful.

The condition, however, is not contagious.

According to the National Psoriasis Foundation, the skin disease affects 8 million Americans and more than 125 million people worldwide.

The condition impacts physical comfort and quality of life, especially when lesions are on visible or sensitive areas.

The plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales. They can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.

Who Can Use Icotyde

Icotyde is currently approved in the US for the treatment of people with moderate-to-severe plaque. It can be used by

• adults, and pediatric patients 12 years of age and older
• who weigh at least 40 kg.